Unlock instant, AI-driven research and patent intelligence for your innovation.

H3N2 subtype swine influenza virus cell adapted strain, inactivated vaccine prepared from H3N2 subtype swine influenza virus cell adapted strain, and applications of H3N2 subtype swine influenza virus cell adapted strain

A swine flu virus, H3N2 technology, applied in the direction of antisense single-stranded RNA virus, vaccine, virus, etc., can solve the problems of loose virus and high production cost, and achieve the generation of induced specific antibodies, good safety and immune effect good effect

Active Publication Date: 2018-06-08
哈药集团生物疫苗有限公司
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, because it uses chicken embryos for vaccine preparation, not only the production cost is relatively expensive, but also chicken embryo waste needs to be disposed of, and there is a danger of spreading the virus. Therefore, it will be cheaper and safer to use cells for vaccine preparation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • H3N2 subtype swine influenza virus cell adapted strain, inactivated vaccine prepared from H3N2 subtype swine influenza virus cell adapted strain, and applications of H3N2 subtype swine influenza virus cell adapted strain
  • H3N2 subtype swine influenza virus cell adapted strain, inactivated vaccine prepared from H3N2 subtype swine influenza virus cell adapted strain, and applications of H3N2 subtype swine influenza virus cell adapted strain
  • H3N2 subtype swine influenza virus cell adapted strain, inactivated vaccine prepared from H3N2 subtype swine influenza virus cell adapted strain, and applications of H3N2 subtype swine influenza virus cell adapted strain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1H3

[0038] Isolation and Identification of Example 1 H3N2 Subtype Swine Influenza Virus Strains

[0039] 1. Chicken embryo and disease material

[0040] SPF chicken embryos were purchased from Beijing Meria Weitong Experimental Animal Technology Co., Ltd.; disease materials were collected from nasal swabs and lung tissues suspected of swine flu from a pig farm in Heilongjiang. Grind the disease material with a grinder, freeze and thaw repeatedly 3 times, mix it with PBS (0.1mol / L, pH 7.2) at 1:5 (V / V), centrifuge at 3000r / min for 15min, take the supernatant, and pass through 0.22 After sterilizing with a μm filter membrane, store at -70°C for later use.

[0041] 2. Virus isolation

[0042] The above supernatant was inoculated into 5 10-day-old SPF chicken embryos through the allantoic cavity, 0.2ml / embryo, cultured in a 35°C incubator (humidity kept at 60-65%), and the embryos were checked twice a day, within 24 hours. The dead chicken embryos were discarded, and the dead chick...

Embodiment 2

[0071] Example 2 The production process of culturing swine influenza H3N2 subtype virus with bioreactor

[0072] 1) Screening and recovery of cells

[0073] When MDCK cells are cultured and passaged, the serum content in the culture medium is gradually reduced, and finally cells that can adapt to serum-free medium culture are obtained, and a cell seed batch for serum-free culture is established. The above cells were subjected to full suspension adaptation culture in a shaker flask, and screened through single cell clones to finally obtain an MDCK cell line that could be adapted to full suspension culture (the MDCK cell line was selected and bred by Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. for sale abroad).

[0074] After the cryopreserved MDCK cells were taken out from the liquid nitrogen, they were immediately thawed in a 37°C water bath, transferred to a 75ml cell flask with a pipette, and an appropriate amount of DMEM medium (containing 6% fetal bovine seru...

Embodiment 3

[0085] Example 3 Preparation of swine influenza H3N2 subtype inactivated vaccine and evaluation of its safety and immune efficacy

[0086] 1) Preparation of virus liquid for seedling production

[0087] The virus liquid prepared in Example 2 was used as the virus liquid for vaccine preparation.

[0088] 2) Preparation of virus inactivator vaccine

[0089] The virus solution harvested above was added with BEI with a final concentration of 0.2% (m / v, g / mL), inactivated at 30°C for 36 hours, and then added with thiosulfuric acid with a final concentration of 0.2% (m / v, g / mL). sodium. Mix the virus liquid of H3N2 subtype swine influenza virus cell-adapted strain SIV-H3N2-HLJ strain with qualified inactivation test according to the ratio of Montanide ISA 15A VG adjuvant=9:1 (v / v), first add the water phase Slowly stir in the emulsification tank, then slowly add the oil phase adjuvant, stir at 800 r / min for 30 minutes after adding, and then stand still for 30 minutes to prepare t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a H3N2 subtype swine influenza virus cell adapted strain, an inactivated vaccine prepared from H3N2 subtype swine influenza virus cell adapted strain, and applications of the H3N2 subtype swine influenza virus cell adapted strain. The H3N2 subtype swine influenza virus cell adapted strain SIV-H3N2-HLJ is disclosed for the first time; and the preservation number is CGMCC No.14740. The invention also discloses applications of the H3N2 subtype swine influenza virus cell adapted strain SIV-H3N2-HLJ in preparation of vaccines used for preventing swine influenza. The invention also discloses a vaccine composition used for preventing swine influenza. The vaccine composition comprises a prevention effective dose of the inactivated H3N2 subtype swine influenza virus cell adapted strain SIV-H3N2-HLJ and a pharmaceutically acceptable adjuvant. The H3N2 subtype swine influenza virus cell adapted strain SIV-H3N2-HLJ possesses excellent immunogenicity, is capable of providingpigs with excellent immunization protection, and can be taken as a candidate vaccine strain in prevention and control of H3N2 subtype swine influenza.

Description

technical field [0001] The present invention relates to a H3N2 subtype swine influenza virus cell-adapted strain, and also relates to an inactivated vaccine prepared by the H3N2 subtype swine influenza virus cell-adapted strain and its application in preventing swine influenza, belonging to H3N2 subtype swine influenza virus Separation and application fields. Background technique [0002] Swine influenza (SI) is an acute, febrile, highly contagious respiratory infectious disease caused by type A influenza virus. The disease is highly contagious and has a high incidence rate. Its clinical symptoms include coughing, sneezing, runny nose, elevated body temperature, dyspnea, loss of appetite, and delayed slaughter. The mortality rate of simple infection is not high, but it will cause adverse effects on the growth performance of pigs; mixed infection with other pathogens will aggravate the disease, increase the mortality rate, and cause serious economic losses to the pig industr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N7/00A61K39/145A61P31/16
CPCA61K39/12A61K2039/5252A61K2039/552C12N7/00C12N2760/16121C12N2760/16134C12N2760/16151
Inventor 王静赵辉柴华张智明闫冰梁宛楠于鑫赵刚孙晓峰张凤强
Owner 哈药集团生物疫苗有限公司